PT-141 bremelanotide is a cyclic heptapeptide and an agonist at the MC3R and MC4R melanocortin receptors. It acts on circuits in the central nervous system, not on peripheral vasculature. The FDA has approved it under the brand name Vyleesi® for hypoactive sexual desire disorder in premenopausal women.
From melanotan to bremelanotide: the accidental finding
The origin of the compound is a textbook case of a discovery nobody set out to make.
During research on α-MSH analogs for pigmentation purposes (the line that produced Melanotan II), an unanticipated effect on sexual function was observed in study participants.
That finding spun off into a development program of its own, aimed at isolating the effect on the sexual circuit and minimizing the pigmentary one. The result was bremelanotide, a metabolite of Melanotan II developed as a compound in its own right.
Melanocortin receptors and the central circuit
Bremelanotide is an agonist at the MC3R and MC4R receptors, which are expressed in the central nervous system and play a role in energy balance, behavior, and sexual function.
The distinction that defines the compound: it acts on central circuits related to desire, not on peripheral blood flow. That is a qualitatively different mechanism from the one behind PDE5 inhibitors, and the comparison is developed in its own article.
Its affinity for MC1R, the pigmentation receptor, is lower than that of Melanotan II, though not zero. The difference is one of degree, not of category.
The approved indication and its population
The FDA approval is for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Every word in that indication narrows the scope:
- Acquired: not present all along, but appearing later.
- Generalized: not limited to one specific situation or partner.
- Premenopausal women: the population in which it was studied.
Development included randomized, placebo-controlled phase 3 trials, with outcomes measured through validated instruments for desire and for associated distress.
The results described statistically significant improvements of modest magnitude over placebo. That second half is often left out, and it matters: significant is not the same as large.
Documented adverse effects
The ones reported most often in the trials:
| Effect | Observation |
|---|---|
| Nausea | The most frequent; in a notable fraction of participants |
| Flushing | Frequent |
| Headache | Frequent |
| Injection site reactions | Frequent |
| Focal hyperpigmentation | Described, more likely with repeated administration |
| Transient rise in blood pressure | Documented, along with a drop in heart rate |
That last one gets a section of its own, because it is the one that determines who should not use it.
Cardiovascular considerations
Bremelanotide produces a transient rise in blood pressure and a drop in heart rate after administration. The effect is described as modest in magnitude and limited in duration in the population studied.
For that reason, the label of the approved product sets a contraindication in the presence of uncontrolled hypertension or established cardiovascular disease.
That is an explicit contraindication, not a generic precaution. And it is why medical evaluation beforehand is not a formality: identifying who falls into that group requires measuring blood pressure and assessing cardiovascular risk, which is not something anyone can self-assess.
Combining it with PDE5 inhibitors adds a specific consideration, covered in the comparison article.
What was studied in men versus what was approved
PT-141 bremelanotide was investigated in male erectile dysfunction. That development did not end in approval, and the blood pressure findings are among the factors that shaped its path through routes of administration other than subcutaneous.
The practical consequence is direct: the approval covers one specific indication and one specific population. Any use outside them lacks the backing of those trials, and the safety data belong to the population that was studied.
Batch analytical data for the research material are in its technical sheet. And the usual precision is worth keeping: an approved product and a research compound sharing the same chemical name differ in quality control, chain of custody, package insert, and pharmacovigilance.
What the evidence does not settle
- Long-term use: the trials have a defined horizon.
- Populations not studied: postmenopausal women, men, people with the conditions excluded from the trials.
- The size of the effect: statistically significant and modest, with wide individual variability.
- Interactions with other compounds that affect blood pressure: poorly characterized beyond the label warnings.
Frequently asked questions
Does PT-141 work like Viagra?
No. PDE5 inhibitors act peripherally on blood flow; bremelanotide acts in the central nervous system on circuits related to desire. The mechanisms and the locations are different.
Is it approved for men?
No. The FDA approval covers acquired, generalized hypoactive sexual desire disorder in premenopausal women. There was research in men that did not end in approval.
Why is blood pressure a concern?
Because it produces a documented transient rise, which is why the label of the approved product contraindicates its use in uncontrolled hypertension and in established cardiovascular disease.
Does it cause pigmentation like Melanotan II?
Its affinity for the MC1R receptor is lower, but not zero. Focal hyperpigmentation has been described, more likely with repeated administration.
References
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology, 2019;134(5):899–908. DOI: 10.1097/AOG.0000000000003500
- Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health, 2016;12(3):325–337. DOI: 10.2217/whe-2016-0018
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 2003;994:96–102. DOI: 10.1111/j.1749-6632.2003.tb03167.x
- U.S. Food and Drug Administration. Vyleesi (bremelanotide) — prescribing information. accessdata.fda.gov
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.